Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/12918

Title: European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009)
Authors: Adriaenssens, Niels
Coenen, Samuel
Versporten, Ann
Muller, Arno
Minalu Ayele, Girma
Faes, Christel
Vankerckhoven, Vanessa
Aerts, Marc
Hens, Niel
Molenberghs, Geert
Goossens, Herman
Issue Date: 2011
Abstract: Background: Data on more than a decade of outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe were collected from 33 countries within the European Surveillance of Antimicrobial Consumption (ESAC) project, funded by the European Centre for Disease Prevention and Control (ECDC), using the WHO Anatomical Therapeutic Chemical (ATC)/defined daily dose (DDD) methodology. Methods: For the period 1997-2009, data on outpatient use of systemic MLS aggregated at the level of the active substance were collected and expressed in DDD (WHO, version 2011) per 1000 inhabitants per day (DID). Using a classification based on mean plasma elimination half-life, macrolide use was analysed for trends over time, seasonal variation and composition. Results: Total outpatient MLS use in 2009 varied by a factor of 18 between the countries with highest (11.5 DID in Greece) and lowest (0.6 DID in Sweden) use. MLS use showed high seasonal variation. Short-, intermediate- and long-acting macrolides were the most commonly used agents in 2, 25 and 5 countries, respectively (mainly erythromycin, clarithromycin and azithromycin, respectively). In Sweden, mainly lincosamides (clindamycin) were used. Lincosamide use was observed in all countries, while substantial use of a streptogramin was only seen in France (pristinamycin). For Europe, a significant increase in outpatient MLS use was found, as well as a significant seasonal variation, which increased over time from 1997 to 2009. Relative use of long-acting macrolides and lincosamides significantly increased over time with respect to intermediate-acting macrolides, and relative use of the latter increased with respect to short-acting macrolides. Conclusions: The observed differences between European countries in the levels of MLS use and the extreme seasonal variations in their use suggest that this subgroup of antibiotics is still prescribed inappropriately in many countries.
Notes: [Adriaenssens, Niels; Coenen, Samuel; Versporten, Ann; Muller, Arno; Vankerckhoven, Vanessa; Goossens, Herman] Univ Antwerp, Lab Med Microbiol, Vaccine & Infect Dis Inst VAXINFECTIO, B-2020 Antwerp, Belgium. [Adriaenssens, Niels; Coenen, Samuel] Univ Antwerp, Ctr Gen Practice, Vaccine & Infect Dis Inst VAXINFECTIO, B-2020 Antwerp, Belgium. [Minalu, Girma; Faes, Christel; Aerts, Marc; Hens, Niel; Molenberghs, Geert] Univ Hasselt, Interuniv Inst Biostat & Stat Bioinformat I BIOST, Hasselt, Belgium. [Hens, Niel] Univ Antwerp, CHERMID, Vaccine & Infect Dis Inst VAXINFECTIO, B-2020 Antwerp, Belgium. [Molenberghs, Geert] Catholic Univ Louvain, Interuniv Inst Biostat & Stat Bioinformat I BIOST, B-3000 Louvain, Belgium. niels.adriaenssens@ua.ac.be
URI: http://hdl.handle.net/1942/12918
DOI: 10.1093/jac/dkr456
ISI #: 000297228400005
ISSN: 0305-7453
Category: A1
Type: Journal Contribution
Validation: ecoom, 2012
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version393.3 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.